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Materials and Methods 
General 
All chemicals were purchased from Sigma-Aldrich or Fisher. Primers were ordered from 
Integrated DNA Technology (Table S3). Polymerase, restriction enzymes, and ligase 
were purchased from New England Biolabs. DNA manipulation kits were purchased 
from Qiagen and Thermo Scientific. PCR reactions were carried out using an Eppendorf 
Nexus GSX1 thermocycler with Q5 DNA polymerase. General genetic manipulation of 
E. coli was carried out using standard protocols (1). LC-MS data was obtained using an 
Agilent 6520 accurate-mass Q-TOF LC/MS.  Preparative HPLC was carried out using a 
Phenomenex Luna 10 µm C18 (2) column on a Varian Prostar instrument equipped with 
a PDA detector. Further purification was carried out using a Phenomenex Kinetex 5 µm 
C18 column (100 Å, 150 mm x 4.60 mm) on a Shimadzu HPLC equipped with an SPD-
20A UV-vis detector. NMR spectra were obtained using a Bruker 600 MHz spectrometer 
or a Bruker AvanceIII HD 800 MHz spectrometer unless otherwise noted.  
 
Bacterial strains and culture conditions 
For cloning, E. coli DH5α and E. coli Top10 chemically competent maximum efficiency 
cells were used (Invitrogen).  For heterologous expression, E. coli BL21(DE3) 
chemically competent cells (Agilent) were transformed with vectors containing hsv 
expression constructs (Table S4). The hrpL expression construct in pBAD vector was 
previously described (2). All overnight seed cultures were inoculated with a single 
colony and grown in 5 mL media in 14 mL Falcon culture tubes. Antibiotics were used in 
these concentrations, unless otherwise noted: 10 µg/mL tetracycline, 25 µg/mL 
chloramphenicol, 50 µg/mL kanamycin, 50 µg/mL spectinomycin, or 100 µg/mL 
ampicillin. All cultures for metabolomics were grown in 100 mL media with the 
appropriate antibiotic and 100 µL−2 mL of a saturated overnight culture. All E. coli 
cultures were grown in LB Media (Miller, granulated, Fisher) at 37 °C to an OD600 
between 0.4 and 0.8. E. coli cultures were induced with 0.5 mM IPTG and then were 
incubated at 16 °C overnight, shaking at 225 rpm. P. syringae and P. fluorescens starter 
cultures were grown overnight in King’s B Media (20 g/L Bacto Proteose Peptone #3, 
1% glycerol by volume, 1.5 g/L K2HPO4, and 0.734 g/L MgSO4, dissolved in water). P. 
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syringae cultures containing the pBAD plasmid were induced with 0.2% L-arabinose. All 
other P. syringae pv. tomato DC3000 and P. fluorescens cultures were not induced. 
Wildtype P. fluorescens Pf0-1 harboring the hsv-pBBR5 vector was grown in the 
presence of 50 µg/mL ampicillin and 50 µg/mL gentamycin. P. fluorescens harboring 
both hsv-pBBR5 and the T3SS (Pf0-1 +T3SS) was grown with 25 µg/mL tetracycline 
and 50 µg/mL gentamycin. After reaching an OD600 of >0.6 in King’s B media, P. 
fluorescens and P. syringae cultures were washed with 100 mM MgCl2 and 
resuspended in minimal media (12.8 g/L Na2HPO4 ● 7 H2O, 3 g/L KH2PO4, 0.5 g/L 
NaCl, 1 g/L NH4Cl, 1% glycerol by volume, 0.024 g/L MgSO4, 0.0011 g/L CaCl2, and 
0.18 g/L mannitol, dissolved in water). Once resuspended in minimal media, these 
cultures were grown at 28 °C overnight and 16 °C for another 24 hours shaking at 225 
rpm.  
 
Protein expression and purification 
Large-scale cultures for protein purification were grown in 1 L of media containing the 
appropriate antibiotic and 1−5 mL of overnight culture. At an OD600 of 0.5−0.8, a 
sample of 0.5 mM IPTG was added to induce protein expression. After 16 hours of 
protein expression, cultures were spun down and resuspended in HEPES lysis buffer 
(50 mM HEPES, 150 mM NaCl, 10% glycerol, pH 7.5). Cells were lysed by sonication at 
30% amplitude for 3 minutes (0.5 seconds on and 1.5 seconds off). Cell debris was 
removed by centrifugation at 17,000 rpm for 40 minutes and the supernatant was 
filtered using a 0.45 µm filter (Corning). Each Hsv protein was purified using an AKTA 
FPLC using a 5 mL HiTrap nickel column (GE) at a flow rate of 3.0 mL/min. Wash buffer 
consisted of 50 mM HEPES, 150 mM NaCl, 25 mM imidazole, and 10% glycerol (pH 
7.5). Elution buffer was the wash buffer with the addition of 250 mM imidazole. The 
wash step lasted for 5 column volumes (CVs). The proteins were eluted using a 
gradient of 0−100% of elution buffer over 10 CVs, and then held at 100% for 5 CVs. 
HsvB and HsvC were further purified using a HiLoad 16/600 Superdex 200 prep grade 
size exclusion column (GE) on the FPLC using the lysis buffer described above. The 
column was equilibrated with lysis buffer at a flow rate of 0.5 mL/min for 1.5 CVs, then 
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protein was loaded onto the column and eluted over 1.5 CVs using the same buffer and 
flow rate. 
 
Amidinotransferase substrate assay conditions 
To identify the preferred substrates of the amidinotransferase protein HsvA, L-arginine 
was incubated with potential substrates that accept the amidino group. Each reaction 
mixture contained two amino acids at 10 mM each (L-Arg and L-Lys, L-Arg and 
spermidine, or L-Arg and spermine). Each mixture also contained 100 mM HEPES (pH 
7.5) and 20 µM purified HsvA to a final volume of 50 µL.  Samples were incubated at 37 
°C for 2 hours. Enzymes were omitted in negative controls. A sample of 10 µL was 
injected onto a Gemini C18 column (Phenomenex) on LC-MS and separated with a 
gradient of 2−73% acetonitrile (0.1% formic acid) over 25 minutes. This assay showed 
that HsvA catalyzes the transfer of the amidino group from L-Arg to spermidine, 
spermine, or L-lysine. Based on peak areas, the amidinospermidine product is present 
at the highest level, suggesting spermidine is the preferred substrate. 
 
ATP-grasp substrate assay conditions 
A malachite green dye assay (PiColorLock, Innova Biosciences) was used to identify 
the preferred substrates of the ATP-grasp enzyme HsvB by quantifying free phosphate 
(Pi) release. Substrate assays were conducted in 100 µL scale in a microcentrifuge 
tube, and consisted of 2.0 mM amino acids, 10 µM of each enzyme, 10 mM MgCl2, 5 
mM ATP, and 50 mM HEPES (pH 7.5). After 30 minutes, reactions were diluted 1 in 10 
with DI water into a 96-well plate to a final volume of 200 µL, then 50 µL Gold mix 
reagent and 20 µL stabilizer were added. After 30 minutes of incubation, UV-vis 
absorption of the products at 635 nm was measured on a Tecan infinite M1000 Pro 
plate reader. Assays containing L-Phe produced the most Pi, indicating that HsvB 
preferentially activates L-Phe. 
 
Characterization of phevamine biosynthetic pathway 
Sequential assays were conducted to elucidate the biosynthesis of phevamine A. Based 
on the structures of prephevamine, amidinotransfer by HsvA or condensation with L-Val 
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by HsvC may occur as the first step. This rationale led us to examine three potential 
biosynthetic pathways: HsvA → C → B, HsvC → A → B, and HsvC → B → A. An initial 
assay was conducted for either HsvA or HsvC. The HsvA assay consisted of 10 mM L-
arginine, 10 mM spermidine, 100 mM HEPES (pH 7.5), 20 µM HsvA, and water in a 100 
µL volume. Protein was removed after a 30 minute incubation at room temperature 
using a 3000 Da Amicon Ultra filter (Millipore) and the small molecule filtrate was 
collected. To this assay mixture, we added 2 mM MgCl2, 1 mM ATP, 2 mM L-valine, and 
10 µM HsvC. Protein was again removed after 30 minutes at room temperature with a 
3000 Da filter and an aliquot was collected for LC-MS analysis. Finally, 2 mM L-
phenylalanine and 10 µM HsvB were added, and the reaction was incubated at room 
temperature for 30 minutes before the reaction was quenched with acetonitrile at a ratio 
of 1:1 for 15 minutes, precipitated protein was removed by centrifugation, and the 
supernatant was analyzed by LC-MS. The initial HsvC assays consisted of 2 mM 
spermidine, 2 mM L-valine, 100 mM HEPES (pH 7.5), 2 mM MgCl2, 1 mM ATP, 10 µM 
HsvC, and water in a 100 µL volume. After 30 minutes at room temperature, HsvC was 
removed with a 3000 Da filter. To one set of assays, 10 mM L-arginine and 20 µM HsvA 
were added. To the other set of assays, 2 mM L-phenylalanine and 10 µM HsvB were 
added. Both sets of reactions were incubated at room temperature for 30 minutes 
before removing protein with a 3000 Da filter. Aliquots were taken for LC-MS analysis. 
These reactions were then incubated with the remaining constituents that had not been 
added: 2 mM L-phenylalanine and 10 µM HsvB or 10 mM L-arginine and 20 µM HsvA. 
Reactions were incubated at room temperature for 30 minutes before they were 
quenched with acetonitrile at a ratio of 1:1 and the precipitated protein was removed by 
centrifugation. All aliquots were diluted 5 folds with water for LC-MS analysis. 
Phevamines were only produced when the reaction order was HsvA → HsvC → HsvB 
(Figure S10). 
 
Purification of phevamine A 
Assay supernatants were concentrated under reduced pressure and injected onto the 
prep HPLC at a flow rate of 15 mL/min with water and acetonitrile (both containing 0.1% 
trifluoroacetic acid) as mobile phases. The solvent gradient was held at 2% acetonitrile 
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for 10 minutes, then 5% acetonitrile for 5 minutes, and 10% acetonitrile for 15 minutes, 
before being ramped up to 95% over another 20 minutes. Fractions containing 
phevamine A (28–30 min retention time) were concentrated under reduced pressure 
and injected onto the analytical HPLC using the same mobile phases as those for the 
prep HPLC. The solvent gradient ramped from 2−30% acetonitrile over 35 minutes 
before ramping up to 95% for another 8 minutes (flow rate: 0.5 mL/min). Fractions 
containing phevamine A were collected at retention times of 20−25 minutes, and 
concentrated. To separate the two regio-isomers, a final round of purification was 
conducted on the analytical HPLC with an extended gradient at 10−20% acetonitrile for 
25 min. Specifically, the solvent gradient started at 2−5% acetonitrile over 5 minutes, 
then 5−10% over another 5 minutes, and finished with 10−20% for another 25 minutes 
(flow rate: 0.5 mL/min). Fractions with retention times between 17.5–19.5 minutes were 
collected and concentrated. LC/MS analysis showed that the concentrated sample 
contained ~95% pure phevamine A (67% yield). 
 
NMR spectroscopy for phevamine A and B 
All spectra for in vitro purified phevamine A and B were obtained using a Bruker 
AvanceIII HD (800 MHz 1H reference frequency, 201 MHz for 13C) equipped with a 5 mm 
CPTCL 1H-13C/15N cryo probe. Non-gradient phase-cycled dqfCOSY spectra were 
acquired using the following parameters: 0.6 s acquisition time, 400−600 complex 
increments, 8, 16 or 32 scans per increment. Non-gradient HSQC and HMBC spectra 
were acquired with these parameters: 0.25 s acquisition time, 200−500 complex 
increments, 8−64 scans per increment. 1H, 13C-HMBC spectra were optimized for JH,C = 
6 Hz. HSQC spectra were acquired without decoupling. NMR spectra were processed 
and baseline corrected using Mestrelabs MNOVA software packages. NMR 
assignments are shown in Tables S5 and S6.  
 
Metabolite dependence on T3SS 
The hsv operon was cloned into the pBBR5 plasmid containing a constitutive promoter 
and gentamycin resistance marker (3). P. fluorescens Pf0-1 and Pf0-1 + T3SS were 
both transformed with hsv-pBBR5 by electroporation using the method described by 
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Choi and Schweizer (4). Cultures (100 mL) were grown and extracted as described 
above to detect phevamine production and determine whether phevamine secretion is 
dependent on T3SS (Fig. S7). 
 
Generation of Pseudomonas clean deletion mutants 
Pseudomonas knockout clones were generated using MTN1907, a modified version of 
pLVC-D, which allows for SacB counter-selection (2, 5, 6). Overlapping primers 
MT1881, MT1880, MT1877, and MT1878 (Table S3) were used to generate a chimeric 
fragment composed of the ~200 bp sequence upstream of hsvA fused to the ~200bp 
region downstream of hsvC. The chimeric fragment was sub-cloned into MTN1907 and 
Pseudomonas was transformed with the plasmid to obtain a merodiploid after 
recombination. Two merodiploids, with a 3’ end and a 5’ end insertion, were selected to 
generate two independent Pseudomonas clones with clean hsv deletion for each 
parental strain (Pto DC3000, Pto-Cor –, PtoΔhrcC, PtoD28E) after growth on media 
containing 5% sucrose for the second recombination (see Fig. S29 and S30). For 
complementation, the hsv operon was sub-cloned into pBAV226 downstream of the 
NptII promoter (8) and transformed into PtoD28EΔhsv2 (see Fig. S30). The pBAV226 
vector contains the sequence encoding the HA-tag downstream of the gateway 
cassette, but the HA tag was not included in the product of hsvC because the stop 
codon was retained.  
 
Calcium burst measurement 
Leaf disks of 3- to 4-week-old A. thaliana lines pMAQ2 expressing the apoaequorin 
gene under the control of the cauliflower mosaic virus 35S promoter (7) were collected 
in a 96-well plate and incubated overnight with 100 µM coelenterazine native 
(BYOSYNTH) (7). Luminescence was measured as in the ROS burst assay, with the 
exception that luminol and HRP were excluded from the reaction mix. 
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Synthesis of phevamine A 
General information 
Chemicals were purchased from commercial suppliers and used without further 
purification. Fmoc-derivatized amino acids were purchased from Alfa Aesar.  N1, N4-bis-
boc-spermidine was purchased from Chem-Impex International. Diethylamine and 
DIPEA were purchased from Sigma-Aldrich. N,N′-Di-Boc-1H-pyrazole-1-carboxamidine 
and trifluoroacetic acid were purchased from Acros Organics. HATU was purchased 
from Oakwood Products Inc. NMR solvents were purchased from Cambridge Isotope 
Laboratories. Normal-phase column chromatography was performed on silica gel 
(230−400 mesh). Reversed-phase chromatography was performed on C18-bonded 
silica, either on Phenomenex Kinetex C18 or Phenomenex Luna C18. High-resolution 
mass spectra (HRMS) were obtained using an Agilent 6520 Q-TOF LC/MS. Proton, 
carbon and fluorine magnetic resonance spectra (1H NMR, 13C NMR, and 19F NMR) 
were recorded on a Bruker model DRX 400 or 600 (1H NMR at 400 MHz or 600 MHz, 
13C NMR at 101 MHz or 151 MHz) or on a Bruker AVANCE III-OneBay500 (13C NMR at 
235 MHz) spectrometer. NMR experiments are reported in δ units, parts per million 
(ppm), and were referenced to CDCl3 (δ 7.26 ppm for 1H and 77.0 ppm for 13C), DMSO 
(2.50 ppm), MeOD (3.31 ppm) or D2O (4.79 ppm) as internal standards. 1H NMR data 
are reported as follows: chemical shift, multiplicity (s = singlet, bs = broad singlet, d = 
doublet, dd = doublet of doublets, t = triplet, td = triplet of doublets, m = multiplet), 
coupling constants (Hz), and integration.  
 
N-Boc-1,3-diaminopropane (1) 
 
This synthesis followed a similar procedure as Kaur et al. (8). 1,3-Diaminopropane (3 g, 
40.5 mmol, 1 eq.) was dissolved in a 10% solution of Et3N in MeOH (30 mL); the 
mixture was cooled to 0 °C. In a flame dried flask, di-tert-butyl dicarbonate (4.4 g, 20 
mmol, 0.5 eq.) was dissolved in MeOH and added to the cooled solution (via addition 
funnel). The reaction mixture, which did not appear homogeneous, was stirred overnight 
at room temperature (RT). The solvent was then removed under reduced pressure. The 
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crude mixture was treated with 10% Na2CO3 (10 mL, three times) and extracted with 
CH2Cl2. The combined organic phases were dried over anhydrous Na2SO4 and the 
solvent was removed under reduced pressure. The desired product (1) was obtained as 
a white solid (1.65 g, 23% yield) and used in the subsequent step without further 
purification.  
1H NMR (400 MHz, CDCl3) δ 1.20 (bs, 1H), 1.44 (s, 9H), 1.64-1.57 (m, 2H), 2.76 (t, J = 
6.6 Hz, 2H), 3.22-3.16 (m, 2H), 4.90 (bs, 1H). 
 
N-(4-(3-Boc-1,3-diaminopropane)butyl)phthalimide (2)  
 
This reaction followed a procedure similar to that used by Wang et al. (2012) (9). N-Boc-
1,3-diaminopropane (1.38 g, 7.9 mmol, 1.1 eq.)  was dissolved in MeCN (15 mL) at RT 
and K2CO3 (3.43 g, 24.8 mmol, 5 eq.) was added. N-(4-Bromobutyl)phthalimide (2.2 g, 
7.7 mmol, 1 eq.) was then added and the reaction mixture was heated to 50 °C and 
stirred at this temperature for 18 hours. Subsequently, the mixture was warmed up to 
RT and treated with H2O. The mixture was extracted with EtOAc; the combined organic 
phases were dried over anhydrous Na2SO4 and the solvent was removed under 
reduced pressure. The desired product (2) was obtained (3 g, quantitative yield) and 
used in the subsequent step without further purification. 
1H NMR (400 MHz, CDCl3) δ 1.90−1.82 (m, 2H), 1.40 (bs, 9H), 1.65-1.56 (m, 2H), 
1.75−1.69 (m, 2H), 2.39−2.36 (m, 2H), 3.20-3.13 (m, 4H), 3.71−3.64 (m, 2H), 4.96 (bs, 
1H), 7.75−7.72 (m, 2H), 7.82−7.79 (m, 2H), 
 
N-(4-(N1,N3-bis-Boc-1,3-diaminopropane)butyl)phthalimide (3)  
 
This reaction followed a similar procedure to that was used by Wang et al. (2014) (10). 
The substrate was dissolved in methanol (40 mL) and di-tert-butyl dicarbonate (1.7 g, 
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7.8 mmol, 1 eq.) was added. The reaction mixture was stirred at RT for 12 hours, then 
the solvent was removed under reduced pressure. The Boc-bisprotected product (3) 
was obtained as a pale, yellow oil (3.3 g, 87% yield) and used in the subsequent step 
without further purification. 
1H NMR (400 MHz, CDCl3) δ 1.45−1.44 (m, 2H), 1.70−1.67 (m, 5H), 1.95−1.85 (m, 1H), 
2.42 (bs, 2H), 3.27−3.10 (m, 4H), 3.76−3.70 (m, 2H), 7.75−7.72 (m, 2H), 7.88−7.84 (m, 
2H). 
 
N1, N4-bis-Boc-spermidine (4) 
 
This reaction used a procedure similar to that was used by Wang et al. (2014) (10). To a 
solution of tert-butyl (3-((tert-butoxycarbonyl)amino)propyl)(4-(1,3-dioxoisoindolin-2-
yl)butyl)carbamate (3) (780 mg, 1.64 mmol) in EtOH (30 mL), hydrazine hydrate (0.83 
mL) was added and the reaction mixture was stirred for 12 hours at RT. The solvent 
was removed under reduced pressure and the residue was suspended in 10% ammonia 
and extracted with CHCl3; the combined organic phases were dried on anhydrous 
Na2SO4 and the solvent was removed under reduced pressure. The desired product (4) 
was obtained as a pale, yellow oil (340 mg, 60% yield) and used in the subsequent step 
without further purification.  
1H NMR (400 MHz, CDCl3) δ 1.48−1.46 (m. 18H), 1.66−1.57 (m, 7H), 2.43−2.40 (m, 
1H), 2.49−2.46 (m, 1H), 2.74−2.71 (m, 1H), 3.26−3.12 (m, 4H), 3.69 (bs, 1H), 4.90 (bs, 
1H), 5.78, 5.64 (bs 1H). 
 
Fmoc-(S)-Val-bis-Boc-spermidine (5) 
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To a solution of N1, N4-bis-Boc-spermidine (4) (250 mg, 0.724 mmol, 1.0 eq.) in CH2Cl2 
(20 mL) on ice, Fmoc-Val-OH (295 mg, 8.68 mmol, 1.2 eq.), and DIPEA (252.2 µL, 
1.448 mmol, 2.0 eq.) were added. The reaction was stirred at room temperature for 16 
hours. The crude reaction mixture was purified by flash chromatography (hexanes/ethyl 
acetate gradient) to afford pure product (5) (310 mg, 64% yield) as a white solid.  
1H NMR (400 MHz, CDCl3) δ 0.97 (m, 6H), 1.46 (s, 9H), 1.47 (s, 9H), 1.52 (m, 2H), 1.66 
(m, 2H), 2.15 (m, 2H), 3.07-3.35 (m, 9H), 4.23 (t, J = 7.0 Hz, 1H), 4.36 (m, 1H) 4.44 (m, 
1H), 7.32 (t, J = 7.4 Hz, 2H), 7.42 (t, J = 7.6 Hz, 2H), 7.61 (d, J= 7.6 Hz, 2H), 7.78 (d, J 
= 7.2 Hz, 2H). 
 
Fmoc-(S)-Phe-(S)-Val-bis-Boc-spermidine (6) 
 
To a solution of Fmoc-(S)-Val-bis-Boc-spermidine (5) (310 mg, 0.465 mmol, 1.0 eq) in 
20 mL MeCN, diethylamine (500 L, 2.5% v/v) was added. The reaction was stirred at 
room temperature for 2 hours. The crude reaction mixture was concentrated under 
reduced pressure. Ethyl acetate (25 mL) was added, and the reaction mixture was 
concentrated again. The crude reaction mixture was dissolved in CH2Cl2 (20 mL) and 
added to a mixture of Fmoc-Phe-OH (216 mg, 0.558 mmol, 1.2 eq.), HATU (269 mg, 
0.6975 mmol, 1.5 eq.), and DIPEA (162 µL, 0.742 mmol, 2.0 eq.) previously kept under 
stirring for 20 minutes on ice. The reaction was stirred at room temperature for 16 
hours. The crude reaction mixture was purified by flash chromatography (hexanes/ethyl 
acetate gradient) to afford pure product (6) (190 mg, 50% yield) as a white solid. 
 1H NMR (400 MHz, CDCl3) δ 0.87 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H), 1.47 (s, 
18H), 1.51 (m, 2H), 1.69 (m, 2H), 2.19 (m, 2H), 3.05−3.35 (m, 11H), 4.19 (t, 1H), 4.31 
(m, 1H), 4.41 (m, 1H), 4.51 (m, 1H), 7.20 (m, 2H), 7.31 (m, 5H), 7.41 (t, J = 7.4 Hz, 2H), 
7.54 (d, J = 7.6 Hz, 2H), 7.77 (d, J = 7.2 Hz, 2H). 
SI 13 
 
Fmoc-(S)-Phe-(S)-Val-spermidine (7) 
 
A solution of Fmoc-(S)-Phe-(S)-Val-bis-Boc-spermidine (6) (60 mg, 0.072 mmol) in 
CH2Cl2 (2 mL) was cooled to 0 °C and 800 μL of trifluoroacetic acid was added 
dropwise. The reaction was stirred at room temperature for 3 hours. The crude reaction 
mixture was concentrated under reduced pressure. Toluene was added, and the sample 
was concentrated under reduced pressure until dry. The pure product (7) (23 mg, 32% 
yield over two steps) was obtained as a white solid: 1H NMR (400 MHz, MeOD) δ 0.96 
(m, 6H), 1.59 (m, 2H), 1.70 (m, 2H), 2.07 (m, 3H), 3.00−3.27 (m, 10H), 4.08 (d, J = 7.2 
Hz, 1H), 4.16 (t, J = 7.0 Hz, 1H), 4.26 (m, 1H), 4.34 (m, 1H), 4.42 (m, 1H), 7.16 (m, 1H), 
7.21−7.32 (m, 5H), 7.40 (t, J = 7.6 Hz, 2H), 7.58 (d, J = 7.6 Hz, 2H), 7.81 (d, J = 7.6 Hz, 
2H); HRMS (EI) m/z [M + H]+ Calculated for C36H48N5O4 614.370, observed 614.371. 
 
Fmoc-(S)-Phe-(S)-Val-spermidine-N,N’-di-Boc-1H-guanidine (8) 
 
To a solution of Fmoc-(S)-Phe-(S)-Val-spermidine (7) in DMF (2 mL), which has been 
cooled to 0 °C, DIPEA (200 µL) and N,N′-Di-Boc-1H-pyrazole-1-carboxamidine (24 mg, 
0.072 mmol, 1.0 eq.) were added. The reaction was stirred for 4 hours at room 
temperature. The crude reaction mixture was purified directly using reverse-phase prep 
HPLC (Phenomenex Luna C18, H2O/MeCN gradient) and then purified using a second 
round of reverse-phase HPLC (Phenomenex Kinetex C18, H2O/MeCN gradient). The 
product (8) was purified as a white solid (23 mg, 37% yield over 2 steps). 1H NMR (600 
MHz, MeOD) δ 0.96 (m, 6H), 1.49 (s, 9H), 1.55 (s, 9H), 1.60 (m, 2H), 1.72 (m, 2H), 1.95 
(m, 2H), 2.07 (m, 1H), 3.02 (m, 4H), 3.14−3.23 (m, 2H), 3.24-3.35 (m, 2H) 3.47 (m, 2H), 
SI 14 
 
4.08 (d, J = 7.2 Hz, 1H), 4.17 (t, J = 7.5 Hz, 1H), 4.26 (m, 1H), 4.35 (m, 1H), 4.42 (m, 
2H), 7.23 (m, 2H), 7.30 (m, 5H), 7.40 (m, 2H), 7.58 (t, J = 6.9 Hz, 2H), 7.81 (d, J = 7.8 
Hz, 2H); HRMS (EI) m/z [M + H]+ Calculated for C47H66N7O8 856.497, observed 
856.499. 
 
Phevamine A (9) 
To a solution of Fmoc-(S)-Phe-(S)-Val-spermidine-N,N’-Di-Boc-1H-guanidine (8) (23 
mg, 0.027 mmol) in 2.5 mL of MeCN, diethylamine (300µL) was added. The reaction 
was stirred for 6 hours at room temperature. The crude reaction mixture was 
concentrated under reduced pressure. Ethyl acetate was added, and the reaction 
mixture was concentrated again. The reaction mixture was dissolved in CH2Cl2 (3 mL) 
on ice and trifluoroacetic acid (350 µL) was added dropwise. The reaction was stirred at 
room temperature for 12 hours. The reaction mixture was concentrated under reduced 
pressure. Toluene was added and the reaction mixture was concentrated until dryness. 
The reaction mixture was purified by reverse-phase HPLC (Phenomenex Kinetex C18, 
H2O/MeCN gradient). The final product phevamine A (9) was obtained as a white solid 
(9.8mg, 67% yield). 1H NMR (400 MHz, D2O) δ 0.79 (d, J = 6.8 Hz, 3H), 0.82 (d J = 6.8 
Hz, 3H), 1.49 (m, 2H), 1.60 (m, 2H), 1.84 (m, 1H), 1.87 (m, 2H), 2.97−3.20 (m, 8H), 3.20 
(t, J = 6.8 Hz, 2H), 3.87 (d, J = 8.4 Hz, 1H), 4.22 (t, J = 7.2 Hz, 1H), 7.15 (m, 2H), 7.29 
(m, 3H); HRMS (EI) m/z [M + H]+ Calculated for C22H40N7O2 434.324, observed 
434.323. 19F NMR (400 MHz, D2O) δ −75.67 (s). 
SI 15 
 
Supplementary Tables 
Name Sequences (5’ to 3’) 
hsv_pLIC-His_sense TACTTCCAATCCAATGCGATGTCATATCAAAAAGCAGAACCCGCTTAC 
 
hsv_pLIC-His_anti 
 
hsv_pBBR5_sense 
 
 
hsv_pBBR5_anti 
 
 
TTATCCACTTCCAATGCGCTATCAACCACGCGCAGCTTCTGCATGC 
 
GACAACAGACTAGTATGTCATATCAAAAAGCAGAACCCG 
(SpeI site underlined) 
 
GACAACAGAAGCTT TCAACCACGCGCAGCTTC 
(HindIII site underlined) 
hsvA_pRSF_BamHI_sense GACAACAGGGATCCGATGTCATATCAAAAAGCAGAAC 
(BamHI site underlined) 
 
hsvA_pRSF_HindIII_anti GACAACAGAAGCTTTCAAATATAACGGTGCAGTCCT 
(HindIII site underlined) 
 
hsvB_pACYC_SacI_sense GACAACAGGAGCTCGATGCGCCCTACAAAAAAAATACTG 
(SacI site underlined) 
 
hsvB_pACYC_HindIII_anti GACAACAGAAGCTTTCACTCCTCAAACGGAGGG 
(HindIII site underlined) 
 
hsvC_pCDF_BamHI_sense GACAACAGGGATCCGATGGACAAAAATAAGCCAAACACTATTCTG A 
(BamHI site underlined) 
 
hsvC_pCDF_HindIII_R 
 
 
MT1797 
 
MT1881 
 
MT1880 
 
MT1877 
 
MT1878 
 
MT1967 
 
MT1968 
 
MT1969 
 
MT1970 
 
MT1971 
 
MT1972 
GACAACAGAAGCTTTCAACCACGCGCAGCTTCTG 
(HindIII site underlined) 
 
GTCCCGGATGAAGTAATCGGATCC 
 
GGGTACTGTCTAACGCCGCTATATTGACTGAAGGGGCG 
 
ATATAGCGGCGTTAGACAGTACCCGTCCGGGCATCCC 
 
CACCGTCTGAGGTTCTGATAGGACGGGG 
 
CTGCGCGACGAAATGCTCGCGGCGG 
 
GGGGTTCGTCCGGCCTTTCCGC 
 
GTGCTGATTGCGAGCACGGTCG 
 
GCTTCAGACCTTCCTCAAGGCG 
 
GTCTAATGGCTGACCGCCACTG 
 
AGAACCCACGTAGTGCCGGCTC 
 
ATGGACGCCATAGGGTGTGTAG 
 
Table S3. Primers used for cloning of the hsv operon, cloning of individual hsv genes in 
E. coli, and generation of hsv knockouts. Nucleotides added for cloning are shown in 
bold. Restriction sites are underlined. 
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Insert Plasmid Host strain Source 
hsvA pRSF-duet (Kan) 
E. coli BL21 This study 
hsvB 
pACYC-duet 
(Cam) 
E. coli BL21 This study 
hsvC pCDF-duet (Sm) 
E. coli BL21 This study 
hsvA-C pLIC-His (Amp) 
E. coli BL21 This study 
  P. fluorescens 
Pf0-1 
(11) 
hrp/hrc  
EthAn Tn5 
transposant of 
P. fluorescens 
Pf0-1 (Tet) 
(12) 
hsvA-C pBBR5 (Gent) P. fluorescens 
Pf0-1 
This study 
  P. syringae pv. 
tomato DC3000 
(2) 
hrpL pBAD (Tet) P. syringae pv. 
tomato DC3000 
(2) 
Tn5::cfa6 (DC3118)  P. syringae pv. 
tomato DC3000 
(13, 14) 
 
Table S4. List of plasmids and strains used in this study. 
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Position δc Proton δH(JHH[Hz]) HMBC 
1 128.49 1-H 7.41(J1,2 = 6.9) 3 
2 129.61 2-H 7.42(J2,1 = 6.9) (J2,3 = 7.1) 2,4 
3 129.86 3-H 7.26(J3,2 = 7.1) 1,3,5 
4 134.07    
5 37.38 5-Ha 3.19(J5a,5b = 14.4) (J5a,6 = 7.5) 3,4,6,7 
  5-Hb 3.23(J5b,5a = 14.4) (J5b,6 = 6.6) 3,4,6,7 
6 54.65 6-H 4.33(J6,5a = 7.5) (J6,5b = 6.6) 4,7 
7 169.28     
8 60.45 8-H 3.98(J8,9 = 8.5)  7,9,10,11,12 
9 30.71 9-H 1.95(J9,8 = 8.5) (J9,10 = 6.8) (J9,11 = 6.8) 8,10,11 
10 18.49 10-3H 0.93(J10,9 = 6.8) 8,9,11 
11 18.75 11-3H 0.90(J11,9 = 6.8) 8,9,10 
12 172.58    
13 39.18 13-Ha 3.15(J13a,13b = 13.3) (J13a,14 = 7.0) 12,14,15 
  13-Hb 3.29(J13b,13a = 13.3) (J13b,14 = 7.0) 12,14,15 
14 26.02 14-2H 1.61(J14,13a = 7.0) (J14,13b = 7.0) (J14,15 = 7.6) 13,15,16 
15 23.65 15-2H 1.73(J15,14 = 7.6) (J15,16 = 7.6) 13,14,16 
16 47.74 16-2H 3.10(J16,15 = 7.6) 14,15,17 
17 45.29 17-2H 3.12(J17,18 = 8.0) 16,18,19 
18 25.47 18-2H 2.00(J18,17 = 8.0) (J18,19 = 6.7) 17,19 
19 38.71 19-2H 3.31(J19,18 = 6.7) 17,18,20 
20 157.38    
 
Table S5. 1H (800 MHz) and 13C (200 MHz) NMR spectroscopic data for phevamine A 
in D2O. Chemical shifts were referenced to δ(CH3CO2H) = 2.08 ppm and δ(13CH3CO2H) 
= 21.03. 13C chemical shifts were determined via HMBC and HSQC experiments. 1H, 
1H-J-coupling constants were determined from the acquired 1H or dqfCOSY spectra. 
HMBC correlations are from the indicated proton(s) to the indicated 13C atom. 
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Position δc Proton δH(JHH[Hz]) HMBC 
1 128.62 1-H 7.35(J1,2 = 7.0) 3 
2 129.78 2-2H 7.38(J2,1 = 7.0) (J2,3 = 7.1) 2,4 
3 129.99 3-2H 7.23(J3,2 = 7.1) 1,3,5 
4 134.05    
5 37.37 5-2H 3.18(J5,6 = 7.0) 3,6,7 
6 54.66 6-H 4.25(J6,5 = 7.0) 4,7 
7 169.12     
8 55.56 8-H 4.64(J8,9a = 8.7) (J8,9b = 7.0)  7,9,13 
9 37.93 9-Ha 2.99(J9a,9b = 13.2) (J9a,8 = 8.7) 10,11 
  9-Hb 3.04(J9b,9a = 13.2) (J9b,8 = 7.0) 10,11 
10 136.40    
11 129.78 11-2H 7.20(J11,12 = 7.5) 9,11,13 
12 129.35 12-2H 7.34(J12,11 = 7.5) (J12,13 = 7.0) 10,12 
13 127.84 13-H 7.30(J13,12 = 7.0)  11 
14 172.18    
15 60.39 15-H 3.85(J15,16 = 8.4) 14,16,18,19 
16 30.81 16-H 1.91(J16,15 = 8.4) (J16,17 = 6.8) (J16,18 = 6.8) 18 
17 18.87 17-3H 0.87(J17,16 = 6.8) 15,16,18 
18 18.72 18-3H 0.91(J18,16 = 6.8) 15,16,17 
19 172.85    
20 39.20 20-Ha 3.08(J20a,20b = 13.5) (J20a,21 = 7.0) 19,21,22 
  20-Hb 3.18(J20b,20a = 13.5) (J20b,21 = 7.0) 19,21,22 
21 26.07 21-2H 1.54(J21,20a = 7.0) (J21,20b = 7.0) (J21,22 = 7.0) 20,23 
22 23.69 22-2H 1.67(J22,21 = 7.0) (J22,23 = 7.8)  20,23 
23 47.80 23-2H 3.05(J23,22 = 7.8) 21,22,24 
24 45.35 24-2H 3.09(J24,25 = 7.8) 23,25,26 
25 25.56 25-2H 1.98(J25,24 = 7.8) (J25,26 = 7.0) 24,26 
26 38.80 26-2H 3.28(J26,25 = 7.0) 24,25,27 
27 157.47    
 
Table S6. 1H (800 MHz) and 13C (200 MHz) NMR spectroscopic data for phevamine B 
in D2O. Chemical shifts were referenced to δ(CH3OH) = 3.34 ppm and δ(13CH3OH) = 
49.50. 13C chemical shifts were determined via HMBC and HSQC experiments. 1H, 1H-
J-coupling constants were determined from the acquired 1H or dqfCOSY spectra. HMBC 
correlations are from the indicated proton(s) to the indicated 13C atom. 
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Supplementary Figures 
 
Figure S1. Plant immune response schematic. Diagram showing several MAMP-
induced immune responses in a plant host cell. Upon elicitation by a MAMP, a plant cell 
may induce MAPK cascade activation, transcriptional reprogramming, calcium burst, 
ROS burst, synthesis of various secondary metabolites, and callose deposition. 
Collectively, these responses are sufficient to suppress pathogen proliferation. MAMP: 
microbe-associated molecular pattern, PRR: pathogen recognition receptor, TF: 
transcription factor, MEKK: mitogen-activated protein (MAP) kinase kinase kinase, 
MKK: MAP kinase kinase, MAPK: MAP kinase, CDPK: calcium-dependent protein 
kinase, ROS: reactive oxygen species. 
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Figure S2. Pto_Δhsv mutants do not display significantly reduced virulence on A. 
thaliana. Bacteria were counted after recovery from Pto-wildtype and Pto_Δhsv mutants 
on A. thaliana seedlings. The experiment was repeated twice with similar results. The 
mutants in both experiments displayed slightly reduced growth but this was not 
statistically significant (Student's t-tests). ns: non significant. Error bars represent ± 
standard error. 
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Figure S3. The hsv operon suppresses callose deposition in A. thaliana induced 
by components encoded by the T3SS locus. Leaves of 4-week-old A. thaliana were 
infiltrated with the P. fluorescens strains noted at bottom and stained with aniline blue, 
~20 h post infiltration. **, p-value ≤ 0.01; t-test. Error bars represent standard errors. 
This experiment was repeated 3 times with similar results. 
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Figure S4. Identification of phevamines by comparative metabolomics. The LC-MS 
metabolic profiles are compared between the extract of E. coli overexpressing hsv and 
E. coli control containing the empty vector.  The fold change (log2) for each metabolite is 
plotted against the p-value (log10) for that metabolite. Data points for prephevamine 
(pPHV), phevamine A (PHVA), and phevamine B (PHVB) are highlighted in red. The 
average fold change is very large for prephevamine (430 fold increase), phevamine A 
(1600 fold increase), and phevamine B (540 fold increase) comparing hsv 
overexpression and the empty vector control. When the fold change for a metabolite is 
large, the level in each sample tends to vary more. The relatively large p-values for 
these metabolites may be due to variable protein levels upon overexpression.  
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Figure S5. Production of prephevamine by different bacterial strains. Extracted ion 
chromatograms are shown for prephevamine (m/z, 287.255) detected in the extracts of 
each bacterial strain. The retention time of prephevamine is approximately 3.8 minutes. 
Prephevamine is not produced by Pto∆hsv (hsv deletion mutant in Pto) (gray). 
Prephevamine is produced by Pto∆hrpL (hrpL deletion mutant in Pto) (orange), wildtype 
Pto (black), Pto pBAD:hrpL overexpression (red), and E. coli overexpressing the hsv 
operon (blue). Prephevamine is also produced in the in vitro enzymatic reaction and 
was purified by HPLC (brown). The in vitro purified standard was co-injected with the 
hrpL overexpression extract (pink) and the wildtype Pto extract (green), both showing a 
single peak for prephevamine. In (D), (E), and (G), the additional prephevamine peaks 
result from in-source fragmentation of phevamine A or phevamine B as labeled. 
Lowering the fragmentor voltage reduced these in-source fragmentation peaks. Two 
metabolites from extractions, 1 and 2, are structurally unrelated to prephevamine based 
on LC/MS/MS analysis. 
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Figure S6. Production of phevamine B by different bacterial strains. Extracted ion 
chromatograms are shown for phevamine B (m/z, 581.392). Phevamine B is not 
produced by Pto∆hsv (hsv deletion mutant in Pto) (orange), Pto∆hrpL (hrpL deletion 
mutant in Pto) (green), wildtype Pto (brown), or Pto pBAD:hrpL overexpression (pink). 
Phevamine B is only detected in E. coli overexpressing hsv (red) and in vitro enzymatic 
reaction (blue).  
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Figure S7. Phevamine A production in P. fluorescens Pf0-1 is independent of 
T3SS. Extracted ion chromatograms of phevamine A (m/z 434.324) are shown. 
Phevamine A is detected in both Pf0-1 strains expressing hsv, Pf0-1+T3SS+hsv (green) 
and Pf0-1+hsv (red), indicating that the T3SS is not required for the secretion of 
phevamine A. Phevamine A is not detected in the culture extracts of control strains 
without hsv, Pf0-1+T3SS (blue) or Pf0-1 (orange). 
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Figure S8. Structural analyses of prephevamine and phevamines by tandem mass 
spectrometry (LC-MS/MS). (A) MS/MS spectrum of prephevamine (m/z 287.255). (B) 
MS/MS spectrum of phevamine A (m/z 434.324). (C) MS/MS spectrum of phevamine B 
(m/z 581.392). 
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Figure S9. Identification of the regioisomers of phevamine A by LC-MS/MS. A 100 
m/z fragment is unique to the amidinotransfer product on the propylamine end of 
spermidine (regioisomer A), and a 114 m/z fragment is unique to the amidinotransfer 
product on the butylamine end of spermidine (regioisomer B). Both isomers are 
detected from the in vitro reaction and E. coli overexpression. In culture extracts of 
wildtype Pto, only regioisomer A was detected.  
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Figure S10. Production of phevamines and detection of pathway intermediates by 
sequential in vitro enzymatic assays. Extracted ion chromatograms are shown for (A) 
amidinospermidine (m/z 188.187) from HsvA reaction, (B) prephevamine (m/z 287.255) 
from HsvA reaction followed by HsvC reaction, and (C) phevamine A (m/z 434.324, 
green) and phevamine B (m/z 581.392, blue) from sequential reactions of HsvA, HsvC, 
and HsvB. In (B), the second small peak for prephevamine comes from in-source 
fragmentation of Compound 3, the mass of which corresponds to Val-Val-Val-
amidinospermidine, an in vitro byproduct of the HsvC reaction. In (C), the second peak 
for phevamine A is the result of in-source fragmentation of phevamine B.  
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Figure S11. In vitro reconstitution of HsvA activity. HsvA was incubated with 
spermine, spermidine, and L-lysine as the acceptor of the amidino group and L-arginine 
as the donor of the amidino group. Extracted ion chromatograms are shown for 
amidinospermidine (m/z 188.187), amidinospermine (m/z 245.245), and homoarginine 
(m/z 189.135), which are the amidinotransfer products catalyzed by HsvA for 
spermidine, spermine, and arginine, respectively.  
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Figure S12. HsvB activates L-Phe as the preferred substrate. Several pairs of amino 
acids were incubated with HsvB and the released inorganic phosphate (Pi) was 
measured using the PiColorLock assay described in the Methods. The amino acid pairs 
are (A) L-Ser and L-Orn, (B) L-Ala and L-Lys, (C) L-Ala and L-Phe, (D) L-Arg and L-Trp, 
and (E) 2x L-Phe. The assays containing L-Phe ((C) and (E)) produced the most Pi, 
indicating that L-Phe is the preferred substrate for HsvB.  
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Figure S13. Production of phevamine A and B depends on HsvB concentration. 
Reaction mixtures containing 100 µM pPHV, 20 µM Phe, and varying amounts of HsvB 
were incubated at room temperature for 2 hours. As the concentration of HsvB 
increased, the amount of phevamine B (m/z 581.392) increased (pink, red, and blue). 
The ratio of phevamine A (m/z 434.324) (orange, black and green) to phevamine B is 
the highest at low concentration of HsvB. The peak around 11 minute retention time in 
phevamine A traces is a result of in-source fragmentation of phevamine B. 
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Figure S14. 1H NMR (600 MHz) of in vitro synthesized and purified phevamine A. 
Spectrum acquired in D2O. 
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Figure S15. (1H,1H)-dqfCOSY spectrum (800 MHz) of in vitro synthesized and 
purified phevamine A. Spectrum acquired in CD3OD. 
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Figure S16. (1H,13C)-HMBC spectrum (800 MHz) of in vitro synthesized and 
purified phevamine A. Spectrum acquired in CD3OD. 
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Figure S17. (1H,13C)-coupled-HSQC spectrum (800 MHz) of in vitro synthesized 
and purified phevamine A. Spectrum acquired in CD3OD. 
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Figure S18. 1H NMR (600 MHz) of in vitro synthesized and purified phevamine B. 
Spectrum acquired in CD3OD. 
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Figure S19. (1H,1H)-dqfCOSY spectrum (800 MHz) of in vitro synthesized and 
purified phevamine B. Spectrum acquired in CD3OD. 
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Figure S20. (1H,13C)-HMBC spectrum (800 MHz) of in vitro synthesized and 
purified phevamine B. Spectrum acquired in CD3OD. 
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Figure S21. (1H,13C)-coupled-HSQC spectrum (800 MHz) of in vitro synthesized 
and purified phevamine B. Spectrum acquired in CD3OD. 
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Figure S22. 1H NMR (400 MHz) of the phevamine A synthetic standard (9). 
Spectrum acquired in D2O. 
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Figure S23. Iron binding activity of phevamine A. The ability of phevamine A to bind 
iron was tested and compared to EDTA standards using a chromeazurol S (CAS) 
assay. Upon binding of ferric iron, the chromeazurol S dye changes color from blue to 
yellow. No color change was observed for phevamine A at a concentration of up to 10 
mM, thus it is unlikely that phevamine A acts as a siderophore to bind ferric iron. 
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Figure S24. Polyamines enhance the flg22-induced ROS burst in N. benthamiana. 
(A) Various polyamines potentiate the flg22-induced ROS burst. Leaf disks were 
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challenged with 10 nM of flg22 with or without polyamines at 400 µM. Put: putrescine, 
Spd: spermidine, and Spn: spermine. (B) Dose-dependent effect of spermidine on the 
flg22-induced ROS burst. Leaf disks were challenged with 10 of nM flg22 and various 
concentrations of spermidine. (C) The increase of the flg22-induced ROS burst by 
spermidine is not due to an additive effect. Leaf disks were treated with distilled water 
(DW), 10 nM of flg22, 10 nM of flg22 with 400 µM of spermidine, or 400 µM of 
spermidine only. Experiments presented in panels (A) and (C) were performed more 
than 3 times with similar results. The experiment presented in panel (B) was done twice 
with similar results. Error bars represent standard errors.  
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Figure S25. Effect of spermidine on early MTI responses in A. thaliana. (A) 
Spermidine potentiates the flg22-induced ROS burst. Leaf disks were treated with 
distilled water (DW), flg22 at 10 nM, flg22 with spermidine at 300 µM or spermidine only 
at 300 µM. ROS levels were measured. This assay was repeated more than 3 times 
with similar results. (B) Potentiation of the flg22 ROS burst by spermidine is dependent 
on FLS2. Leaf disks from Col-0 or the fls2 mutant were challenged with flg22 only at 20 
nM or with spermidine at 300 µM. This experiment was performed twice with similar 
results. (C) Spermidine potentiates the elf18-induced ROS burst. Leaf disks were 
challenged with DW, elf18 at 50 nM, elf18 supplemented with spermidine at 400 µM, or 
with spermidine only at 400 µM. This experiment was performed twice. (D) Spermidine 
suppresses the flg22-induced calcium burst. Col-0_pMAQ2 leaf disks were treated with 
DW, flg22 at 25 nM, flg22 at 25 nM with spermidine at 400 µM, or with spermidine only. 
This experiment was repeated more than 3 times. Error bars represent standard errors.  
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Figure S26. Arginine potentiates the flg22-induced ROS burst in N. benthamiana. 
(A) L-Arginine potentiates the flg22-induced ROS burst, but L-citrulline does not. flg22 
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was used at 10 nM, arginine and citrulline were used at 400 µM. This experiment was 
performed twice with similar results. (B) Dose-dependent effect of arginine on the flg22-
induced ROS burst. flg22 was used at 100 nM and arginine at various concentrations. 
This experiment was performed twice with similar results.  (C) The increase of the flg22-
induced ROS burst by arginine is not due to an additive effect. flg22 was used at 10 nM 
and arginine at 400 µM. This experiment was repeated at least 3 times with similar 
results. Error bars represent standard errors. 
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Figure S27. Phevamine A, but not prephevamine, suppresses the arginine 
potentiation of the flg22-induced ROS burst in both N. benthamiana and A. 
thaliana. (A) Phevamine A, but not prephevamine, suppresses the arginine ROS 
potentiation in N. benthamiana. flg22 was used at 5 nM; arginine, prephevamine and 
phevamine A at 300 µM. (B) Phevamine A, but not prephevamine, suppresses the 
arginine ROS potentiation in A. thaliana. flg22 was used at 5 nM; arginine, 
prephevamine, and phevamine A at 300 µM. PHVA: Phevamine A, pPHV: 
prephevamine. Experiments are representatives of 3 independent repeats with similar 
results. 
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Figure S28. Arginine and polyamine biosynthetic pathways are targeted by 
pathogens via different mechanisms. Spermidine and L-arginine potentiate the flg22-
induced ROS burst. The role of nitric oxide production in this potentiation remains 
uncertain (15). Phevamine A suppresses the spermidine/L-arginine potentiation of the 
flg22-induced ROS burst. Phaseolotoxin inhibits the synthesis of arginine and 
polyamines pathway by suppressing the activity of ODC and OCT, while phevamine A 
targets the potentiation mediated by spermidine and L-arginine. The effector AvrBsT 
from Xanthomonas campestris pv. vesicatoria (Xcv) interacts (red double arrow) with 
ADC1 in pepper (16). ODC: ornithine decarboxylase, OCT: ornithine 
carbamoyltransferase, ADC: arginine decarboxylase, SPDS: spermidine synthase, 
SPMS: spermine synthase, ROS: reactive oxygen species, NO: nitric oxide, PHVA: 
phevamine A. Double dashed arrows represent pathways with intermediates not shown. 
Reproduced from ref. (17) with permission from American Society for Microbiology. 
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Figure S29. Strategy to generate P. syringae clean deletion mutants. A fusion of 
the 5’ and 3’ flanking region of the hsv operon was generated by chimeric PCR and 
cloned into MTN1907. After transformation of the parental strains (Pto, Pto-Cor –, 
PtoD28E), the first recombination integrates the plasmid either at the 5 ’or 3’ end of the 
hsv operon. Merodiploids are selected on media containing tetracycline and genotyped 
by PCR. The second recombination event either leads to a reversion to the original 
locus or the generation of the clean mutant. Recombined strains were selected on 
plates containing sucrose (5%) and clean deletion mutants were identified by PCR (see 
Figure S30). 
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Figure S30. Genotyping of the clean deletion mutants and the complemented 
strain.  (A) Graphical representation of the plasmids used for molecular manipulation of 
P. syringae. The left panel represents the MTN1907 plasmid used to engineer the 
mutants. The right panel represents the pBAV226 plasmid in which the hsv operon was 
cloned downstream of the NptII promoter for complementation of PtoD28E_∆hsv2. Tet: 
confers resistance to tetracycline; mobA, mobB, mobC: RSF1010 mobilization genes; 
ori: high-copy-number origin of replication; SacB: a secreted levansucrase that renders 
bacteria sensitive to sucrose for counter-selection; KanR_inactive: aminoglycoside 
phosphotransferase gene inactive in P. syringae; pVS1 StaA: the stability protein from 
the Pseudomonas plasmid pVS1; pVS1 RepA: a replication protein; p15A ori: p15A 
origin of replication for propagation in E. coli cells; pVS1 oriV: origin of replication of the 
pVS1 plasmid; Gm: the gentamycin acetyltransferase. (B) Graphical representation of 
the hsv locus in the wildtype parental strains (Pto-WT, Pto-Cor –, PtoD28E), and the 
clean deletion mutants. Arrows represent the primers used for the genotyping. OS: 
operon specific primer, G: genomic primer, KO: knockout primer, +: forward primer, -: 
reverse primer (see Supplementary Table S3 for primer sequences). (C) Analytical 
PCRs performed to confirm the genotype of the mutants generated in this study. PCR 
programs include a 1 min extension time, designed for amplification in mutant strains, 
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but too short for amplification in the wildtype parental strains with the exception of the 
PCRs using operon specific primers. 
 
 
 
 
 
 
 
 
 
SI 52 
 
 
 
 
 
Figure S31. 1H NMR (600 MHz) of in vitro purified prephevamine. Spectrum 
acquired in D2O. 
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Figure S32. 1H NMR (400 MHz) of Fmoc-(S)-Val-bis-Boc-spermidine (5). Spectrum 
acquired in CDCl3. 
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Figure S33. 1H NMR (400 MHz) of Fmoc-(S)-Phe-(S)-Val-bis-Boc-spermidine (6). 
Spectrum acquired in CDCl3. 
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Figure S34. 1H NMR (400 MHz) of Fmoc-(S)-Phe-(S)-Val-spermidine (7). Spectrum 
acquired in CD3OD. 
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Figure S35. 1H NMR (600 MHz) of Fmoc-(S)-Phe-(S)-Val-spermidine-N,N’-di-Boc-
1H-guanidine (8). Spectrum acquired in CD3OD. 
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